Generic Semaglutide
4 articles on Generic Semaglutide, written by Shotlee and medically reviewed for clinical accuracy.
IPM Growth Accelerates to 10.1% as GLP-1 Generics Reshape India's Anti-Diabet...
India's pharmaceutical market (IPM) surged 10.1% year-on-year in March 2026, with anti-diabetic therapies leading at 15.5% growth thanks to generic semaglutide entries. The GLP-1 agonist segment exploded to Rs 15.8 billion in MAT March, nearly tripling YoY. Ind-Ra forecasts sustained 9-10% IPM growth in FY27 amid chronic therapy dominance.
4 min read
Patients Without Coverage Eagerly Await Generic Ozempic in Canada
For Canadians without drug coverage, affording Ozempic remains a major hurdle, especially for weight management beyond diabetes. Patients like 77-year-old Anne Welch watch their spouses benefit while rationing hopes on incoming generic semaglutide. With Health Canada reviewing nine submissions, relief may be near—but timelines and costs remain uncertain.
6 min read
Dr. Trehan Warns: Generic GLP-1 Drugs Shouldn't Be OTC
As generic GLP-1 drugs flood the Indian market post-patent expiry, Dr. Naresh Trehan warns they shouldn't be available over-the-counter due to serious side effects. Government advisories stress medical supervision to prevent misuse. Experts like Dr. Gupta and Dr. Bhattacharya highlight risks of self-medication with semaglutide and liraglutide.
6 min read
Sun Pharma Approved for Generic Wegovy in India
Sun Pharmaceutical Industries secures approval to manufacture and sell generic Wegovy in India. The generic semaglutide, branded Noveltreat, launches after March 2026 patent expiry. Indian firms race to tap the booming GLP-1 weight loss market.
1 min read